Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Allied Innovative Systems Inc (AKA: ALLIS)
Profile last edited on: 1/17/2018      CAGE: 47R18      UEI: SFFKG8THUH55

Business Identifier: new technologies for the healthcare and consumer markets
Year Founded
2000
First Award
2000
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

13 Watchung Avenue, Suite 102
Chatham, NJ 07928
   (908) 904-1100
   info@allisystems.com
   www.allisystems.com
Location: Single
Congr. District: 11
County: Morris

Public Profile

Allied Innovative Systems (ALLIS) is a Research and Development company that develops new technologies for the healthcare and consumer markets. ALLIS is developing enzyme based assay tests to help diagnose HIV, food pathogens, and other antibodies. The company has developed several novel technologies in the diverse fields of clinical diagnostics, high throughput drug screening and drug delivery systems.

Extent of SBIR involvement

User Avatar
Phase I Awards
13
Phase II Awards
7
Conversion Rate
53.85%
Phase I Dollars
$2,416,751
Phase II Dollars
$7,240,648
Total Awarded
$9,657,399

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,434,868
Project Title: Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases
2017 2 NIH $2,346,061
Project Title: Ultra-Sensitive Method for HIV P24 Antigen Detection
2016 2 NIH $1,082,499
Project Title: A New Hemagglutination Method for Blood Grouping
2016 1 NIH $219,104
Project Title: A Multiplex Assay for Early Detection of Cutaneous T-Cell Lymphoma
2015 1 NIH $149,972
Project Title: A Method for the Determination of the Percentage of Cd4 T Cells and Cd4/Cd8 Ratio

Key People / Management

  Simon Bystryak -- President

  Rajiv Bandwar -- Principal Engineer

Company News

There are no news available.